ADAPTIVE BIOTECHNOLOGIES (ADPT) Fundamental Analysis & Valuation

NASDAQ:ADPT • US00650F1093

Current stock price

13.32 USD
+0.15 (+1.14%)
At close:
13.32 USD
0 (0%)
After Hours:

This ADPT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. ADPT Profitability Analysis

1.1 Basic Checks

  • In the past year ADPT has reported negative net income.
  • In the past year ADPT has reported a negative cash flow from operations.
  • In the past 5 years ADPT always reported negative net income.
  • In the past 5 years ADPT always reported negative operating cash flow.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • With a Return On Assets value of -11.60%, ADPT perfoms like the industry average, outperforming 43.86% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -27.19%, ADPT is in line with its industry, outperforming 40.35% of the companies in the same industry.
Industry RankSector Rank
ROA -11.6%
ROE -27.19%
ROIC N/A
ROA(3y)-25.08%
ROA(5y)-24.21%
ROE(3y)-59.64%
ROE(5y)-51.27%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Gross Margin of ADPT (74.24%) is better than 94.74% of its industry peers.
  • ADPT's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5Y-0.76%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ADPT Health Analysis

2.1 Basic Checks

  • ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ADPT has been increased compared to 1 year ago.
  • Compared to 5 years ago, ADPT has more shares outstanding
  • The debt/assets ratio for ADPT is higher compared to a year ago.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • ADPT has an Altman-Z score of 1.08. This is a bad value and indicates that ADPT is not financially healthy and even has some risk of bankruptcy.
  • ADPT has a Altman-Z score (1.08) which is comparable to the rest of the industry.
  • ADPT has a Debt/Equity ratio of 0.58. This is a neutral value indicating ADPT is somewhat dependend on debt financing.
  • ADPT's Debt to Equity ratio of 0.58 is on the low side compared to the rest of the industry. ADPT is outperformed by 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Altman-Z 1.08
ROIC/WACCN/A
WACC11.15%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • ADPT has a Current Ratio of 3.34. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
  • ADPT has a Current ratio of 3.34. This is comparable to the rest of the industry: ADPT outperforms 59.65% of its industry peers.
  • A Quick Ratio of 3.23 indicates that ADPT has no problem at all paying its short term obligations.
  • ADPT has a better Quick ratio (3.23) than 63.16% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 3.23
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ADPT Growth Analysis

3.1 Past

  • ADPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.30%, which is quite impressive.
  • Looking at the last year, ADPT shows a very strong growth in Revenue. The Revenue has grown by 54.77%.
  • ADPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.00% yearly.
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.87%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y14.34%
Revenue growth 5Y23%
Sales Q2Q%51.04%

3.2 Future

  • Based on estimates for the next years, ADPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.58% on average per year.
  • Based on estimates for the next years, ADPT will show a quite strong growth in Revenue. The Revenue will grow by 19.37% on average per year.
EPS Next Y-23.67%
EPS Next 2Y15.08%
EPS Next 3Y22.98%
EPS Next 5Y14.58%
Revenue Next Year6.68%
Revenue Next 2Y14.42%
Revenue Next 3Y16.2%
Revenue Next 5Y19.37%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

1

4. ADPT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ADPT. In the last year negative earnings were reported.
  • Also next year ADPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ADPT's earnings are expected to grow with 22.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.08%
EPS Next 3Y22.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADPT Dividend Analysis

5.1 Amount

  • No dividends for ADPT!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADPT Fundamentals: All Metrics, Ratios and Statistics

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (3/16/2026, 5:20:00 PM)

After market: 13.32 0 (0%)

13.32

+0.15 (+1.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)04-29
Inst Owners100.88%
Inst Owner Change4.57%
Ins Owners2.11%
Ins Owner Change-5.02%
Market Cap2.05B
Revenue(TTM)276.98M
Net Income(TTM)-59.50M
Analysts84.29
Price Target21.27 (59.68%)
Short Float %5.89%
Short Ratio4.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)95.77%
Min EPS beat(2)51.32%
Max EPS beat(2)140.22%
EPS beat(4)4
Avg EPS beat(4)63.67%
Min EPS beat(4)30.19%
Max EPS beat(4)140.22%
EPS beat(8)8
Avg EPS beat(8)38.23%
EPS beat(12)10
Avg EPS beat(12)26.53%
EPS beat(16)14
Avg EPS beat(16)23.58%
Revenue beat(2)2
Avg Revenue beat(2)30.42%
Min Revenue beat(2)18.33%
Max Revenue beat(2)42.52%
Revenue beat(4)4
Avg Revenue beat(4)24.54%
Min Revenue beat(4)16.85%
Max Revenue beat(4)42.52%
Revenue beat(8)8
Avg Revenue beat(8)15.98%
Revenue beat(12)10
Avg Revenue beat(12)9.51%
Revenue beat(16)12
Avg Revenue beat(16)7.04%
PT rev (1m)4.29%
PT rev (3m)2.82%
EPS NQ rev (1m)1.55%
EPS NQ rev (3m)5.93%
EPS NY rev (1m)18.14%
EPS NY rev (3m)15.65%
Revenue NQ rev (1m)0.77%
Revenue NQ rev (3m)2.78%
Revenue NY rev (1m)6.11%
Revenue NY rev (3m)5.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.41
P/FCF N/A
P/OCF N/A
P/B 9.37
P/tB 20.91
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.49
Fwd EYN/A
FCF(TTM)-0.32
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS1.8
BVpS1.42
TBVpS0.64
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.6%
ROE -27.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.24%
FCFM N/A
ROA(3y)-25.08%
ROA(5y)-24.21%
ROE(3y)-59.64%
ROE(5y)-51.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5Y-0.76%
F-Score5
Asset Turnover0.54
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.59%
Cap/Sales 1.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 3.23
Altman-Z 1.08
F-Score5
WACC11.15%
ROIC/WACCN/A
Cap/Depr(3y)27.91%
Cap/Depr(5y)120.49%
Cap/Sales(3y)3.13%
Cap/Sales(5y)11.64%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.87%
EPS Next Y-23.67%
EPS Next 2Y15.08%
EPS Next 3Y22.98%
EPS Next 5Y14.58%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y14.34%
Revenue growth 5Y23%
Sales Q2Q%51.04%
Revenue Next Year6.68%
Revenue Next 2Y14.42%
Revenue Next 3Y16.2%
Revenue Next 5Y19.37%
EBIT growth 1Y63.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.85%
EBIT Next 3Y36.37%
EBIT Next 5Y24.27%
FCF growth 1Y50.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.7%
OCF growth 3YN/A
OCF growth 5YN/A

ADAPTIVE BIOTECHNOLOGIES / ADPT Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ADAPTIVE BIOTECHNOLOGIES?

ChartMill assigns a fundamental rating of 3 / 10 to ADPT.


What is the valuation status for ADPT stock?

ChartMill assigns a valuation rating of 1 / 10 to ADAPTIVE BIOTECHNOLOGIES (ADPT). This can be considered as Overvalued.


Can you provide the profitability details for ADAPTIVE BIOTECHNOLOGIES?

ADAPTIVE BIOTECHNOLOGIES (ADPT) has a profitability rating of 2 / 10.


How financially healthy is ADAPTIVE BIOTECHNOLOGIES?

The financial health rating of ADAPTIVE BIOTECHNOLOGIES (ADPT) is 3 / 10.